Bell2Bell’s latest podcast features Dr. Mark Berger, Chief Medical Officer of Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.
Results Show Combination of REQORSA® and Tagrisso® was Well Tolerated at All Three Dose Levels of Phase 1 Trial with Encouraging Evidence of Efficacy Observed
Designed and Secured by Barsec